Merck Ends Development Of Phase II Artherosclerosis Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III candidates, however, could be potential successors to Zocor.
You may also be interested in...
Merck Gaboxadol Submission Delayed Until Mid-2007
Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.
Merck Gaboxadol Submission Delayed Until Mid-2007
Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.